Research programme: vaccines - FIT Biotech

Drug Profile

Research programme: vaccines - FIT Biotech

Alternative Names: Dengue vaccine - FIT Biotech; Diabetes vaccine - FIT Biotech; Hepatitis C vaccine - FIT Biotech; Malaria vaccine - FIT Biotech; Melanoma vaccine - FIT Biotech; Tuberculosis vaccine - FIT Biotech; Vaccines research programme - FIT Biotech

Latest Information Update: 18 Feb 2016

Price : $50

At a glance

  • Originator FIT Biotech
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ebola virus infections; Human papillomavirus infections; Tuberculosis
  • Discontinued Dengue; Diabetes mellitus; Hepatitis C; Malaria; Malignant melanoma

Most Recent Events

  • 21 Dec 2004 Preclinical trials in Diabetes mellitus in Finland (unspecified route)
  • 21 Dec 2004 Preclinical trials in Hepatitis C in Finland (unspecified route)
  • 21 Dec 2004 Preclinical trials in Malignant melanoma in Finland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top